Showing results (51-60 of 66) with videos related to
Sort By:
Pageof 7
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 20, 2016
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid LeukemiaStacey Zahler, Monica Bhatia, Angela Ricci, et al.Bone Marrow Transplantation|September 6, 2018
Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastomaTal Schechter, Evelio Perez-Albuerne, Tiffany F Lin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II StudyMorris Kletzel, Howard M Katzenstein, Paul R Haut, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2006
Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor StudyJeffrey S Dome, Cecilia A Cotton, Elizabeth J Perlman, et al.Annals of Surgery|February 10, 2010
Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5Robert C Shamberger, James R Anderson, Norman E Breslow, et al.Bone Marrow Transplantation|March 28, 2018
Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantationChristine N Duncan, Ruta Brazauskas, Jiaxing Huang, et al.Pediatric Blood & Cancer|March 21, 2006
Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study GroupDaniel M Green, Cecilia A Cotton, Marcio Malogolowkin, et al.Pediatric Blood & Cancer|June 1, 2007
Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study GroupMarcio Malogolowkin, Cecilia A Cotton, Daniel M Green, et al.Blood|January 18, 2014
Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimensMenachem Bitan, Wensheng He, Mei-Jie Zhang, et al.Transplantation and Cellular Therapy|January 22, 2022
Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell TransplantationTim Bognàr, Imke H Bartelink, Toine C G Egberts, et al.Pageof 7